LON:DNL - Diurnal Group Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: GBX 0
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
GBX 69.98
▼ -1.02 (-1.44%)
1 month | 3 months | 12 months
Get New Diurnal Group Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DNL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DNL

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
GBX 0
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Diurnal Group in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a -100.00% upside from the last price of GBX 69.98.
N/A
The current consensus among 0 polled investment analysts is to n/a stock in Diurnal Group. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/29/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/27/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/25/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/21/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/22/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetDetails
2/13/2018Numis SecuritiesReiterated RatingBuyGBX 185
i
12/18/2017Numis SecuritiesReiterated RatingBuyGBX 185
i
9/6/2017Numis SecuritiesReiterated RatingBuyGBX 169
i
6/15/2017Panmure GordonReiterated RatingBuyGBX 178
i
4/4/2017Numis SecuritiesReiterated RatingBuyGBX 169
i
3/20/2017Numis SecuritiesLower Price TargetBuyGBX 187 ➝ GBX 169
i
3/2/2017Numis SecuritiesReiterated RatingBuyGBX 187
i
1/25/2017Numis SecuritiesReiterated RatingBuyGBX 187
i
12/21/2016Numis SecuritiesReiterated RatingBuyGBX 187
i
11/21/2016Numis SecuritiesReiterated RatingBuyGBX 187
i
10/12/2016Numis SecuritiesReiterated RatingBuyGBX 187
i
7/11/2016Numis SecuritiesBoost Price TargetBuyGBX 184 ➝ GBX 187
i
(Data available from 4/21/2016 forward)
Diurnal Group logo
Diurnal Group plc operates as a specialty pharma company worldwide. The company develops hormone therapeutics for the treatment of chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism, and hypothyroidism. The company offers Alkindi, a replacement therapy for paediatric adrenal insufficiency in Europe. It also develops Chronocort, which completed Phase III clinical trials targeting congenital adrenal hyperplasia and adrenal insufficiency. The company's early stage pipeline products comprise Native Oral Testosterone, a replacement treatment for patients suffering from hypogonadism; siRNA, a short interfering RNA oligonucleotide therapy for patients suffering from adrenocorticotropin-dependent Cushing's syndrome; and T3 modified, a modified-release preparation of T3 (levothyroxine) hormone for patients suffering from hypothyroidism. Diurnal Group plc was incorporated in 2015 and is headquartered in Cardiff, the United Kingdom.
Read More

Today's Range

Now: GBX 69.98
67.50
71.50

50 Day Range

MA: GBX 70.97
55
89

52 Week Range

Now: GBX 69.98
27
97.98

Volume

408,204 shs

Average Volume

496,605 shs

Market Capitalization

£96.81 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Diurnal Group?

The following Wall Street sell-side analysts have issued reports on Diurnal Group in the last twelve months:
View the latest analyst ratings for DNL.

What is the current price target for Diurnal Group?

0 Wall Street analysts have set twelve-month price targets for Diurnal Group in the last year. has the lowest price target set, forecasting a price of £100,000 for Diurnal Group in the next year.
View the latest price targets for DNL.

What is the current consensus analyst rating for Diurnal Group?

Diurnal Group currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for DNL.

What other companies compete with Diurnal Group?

How do I contact Diurnal Group's investor relations team?

Diurnal Group's physical mailing address is Heath Park, CARDIFF, CF14 4UJ, United Kingdom. The company's listed phone number is +44-29-20682069. The official website for Diurnal Group is www.diurnal.co.uk.